Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 7/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30114805 | 1.00 | PTGER4 (0.75) | PTGER4KMT2ATP53AGTR1AGTR2 | |
| SCHEMBL691805 | 0.93 | PTGER4 (0.66) | PTGER4KMT2ATP53AGTR1AGTR2 | |
| SCHEMBL30114954 | 0.93 | PTGER4 (0.66) | PTGER4KMT2ATP53AGTR1AGTR2 | |
| SCHEMBL21470064 | 0.90 | PTGER4 (0.62) | PTGER4KMT2ATP53AGTR1AGTR2 | |
| SCHEMBL30114861 | 0.90 | PTGER4 (0.62) | PTGER4KMT2ATP53AGTR1AGTR2 | |
| SCHEMBL30114829 | 0.88 | PTGER4 (0.59) | PTGER4KMT2ATP53AGTR1AGTR2 | |
| SCHEMBL691506 | 0.88 | PTGER4 (0.59) | PTGER4KMT2ATP53AGTR1AGTR2 | |
| SCHEMBL21470224 | 0.87 | PTGER4 (0.58) | PTGER4KMT2ATP53AGTR1AGTR2 | |
| SCHEMBL30114997 | 0.87 | PTGER4 (0.58) | PTGER4KMT2ATP53AGTR1AGTR2 | |
| SCHEMBL23876637 | 0.86 | PTGER4 (0.75) | PTGER4KMT2ATP53KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253595-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | ASKAT INC. (JP) | 2017-09-07 | — | — | US | claimed |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2016-11-03 | — | — | US | claimed |
| EP-2976105-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | AskAt Inc. (JP) | 2016-01-27 | — | — | EP | claimed |
| WO-2014148053-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2014-09-25 | — | — | WO | claimed |
| EP-2538978-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RaQualia Pharma Inc (JP) | 2013-01-02 | — | — | EP | claimed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | claimed |
| US-20120088723-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RAQUALIA PHARMA INC. (JP) | 2012-04-12 | — | — | US | claimed |
| EP-2422779-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RaQualia Pharma Inc (JP) | 2012-02-29 | — | — | EP | claimed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | claimed |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | ARRYS THERAPEUTICS INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | ARRYS THERAPEUTICS INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11840530-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | ASKAT INC. (JP) | 2023-12-12 | — | — | US | disclosed |
| EP-2976105-B1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC (JP) | 2023-01-04 | — | — | EP | disclosed |
| US-20210290641-A1 | EP4 INHIBITORS AND USE THEREOF | ASKAT INC. (JP) | 2021-09-23 | — | — | US | disclosed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120088723-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RAQUALIA PHARMA INC. (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2422779-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RaQualia Pharma Inc (JP) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290641-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | PTGER4 1/4885KMT2A 1165/4885TP53 176/4885 |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | PTGER4, PTGER3, IL23R | PTGER4 1/4885KMT2A 2994/4885TP53 4343/4885 |
| US-20170253595-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885KMT2A 2765/4885TP53 1113/4885 |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PTGER4 51/4885KMT2A 2917/4885TP53 4389/4885 |
| US-11840530-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885KMT2A 2658/4885TP53 1110/4885 |
| US-20120088723-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885KMT2A 2492/4885TP53 1229/4885 |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885KMT2A 3121/4885TP53 3880/4885 |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | PTGER4 1/4885KMT2A 1165/4885TP53 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.